ArticleInflammopharmacology2026
Mechanistic insight into anti-inflammatory activity of Fagonia cretica via COX inhibition and multimodal pharmacological evaluation.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The application of natural plant-based medicine has sparked a great interest in Fagonia cretica, a traditional herb with medicinal properties. However comprehensive evidence regarding anti-inflammatory mechanism remains limited. This study aimed to evaluate phytochemical, anti-inflammatory and toxicological profiles of Fagonia cretica ethanolic extract (EEFC). EEFC was prepared by Soxhlet extraction, and bioactive components were identified using GC-MS analysis. According to OECD guidelines, Swiss albino rats were orally administered at different doses in acute and subacute toxicity. GC-MS analysis revealed 30 phytocompounds with Octan-2-yl palmitate, Pyridine-3-carboxamide, and 2-Ethylhexyl stearate present abundantly. In acute and subacute toxicity, EEFC did not induce any toxicity or mortality, as well as no significant change in blood parameters. Bovine serum albumin assay (BSA), EEFC manifested significant concentration-dependent inhibition of protein denaturation at 50,100, 250, 500, and 1000 µg/ml (IC
Indexed as
Identifiers
42371377What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.